BioStock: Curasight eagerly awaiting phase II-results in brain cancer

Looking back at the time since Curasight first IPO’ed two years ago, CEO Ulrich Krasilnikoff sees a period where a lot has happened. With positive phase II results in several cancer indications for drug candidate uTRACE the company is now eagerly awaiting yet another set of results from the study in brain cancer. BioStock has contacted Krasilnikoff to learn more about the recently released Q3 report and what lies ahead for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/12/curasight-eagerly-awaiting-phase-ii-results-in-brain-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se